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Summary 
Heterogeneous in size (0.1-1 µm), microparticles are small membrane vesicles released from 
activated and/or apoptotic cells. Although described since 1967 by Wolf [1], it is only since 
the 1990’s that microparticles have been considered as biomarkers as well as potential 
mediators of biological messages between cells [2] by acting as paracrine and endocrine 
vectors. Detection of microparticles has been performed in biological fluids (blood, synovial 
fluid, saliva for instance) and some solid tissues but also from the  culture medium [3]. Levels 
of circulating microparticles are enhanced in a large number of pathological states including 
cardiovascular and metabolic disorders associated with insulin resistance and this has been 
linked to deleterious effects on cells from the vascular wall, mainly, endothelial cells. This 
review highlights the increasing impact of microparticles in major cardiovascular pathological 
situations associated with metabolic derangements. 
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Introduction 
Microparticles, small vesicles (0.1-1µm) released from the plasma membrane of activated 
and/or apoptotic cells, are considered as veritable vectors of biological information. Although 
generation of microparticles from cells is a universal event in cell life, little is known about 
the mechanisms regulating this process. Much evidence suggests that microparticles are 
generated at low levels by cells under physiological conditions; however, in a 
pathophysiological environment, increased production of microparticles is common. Recent 
review articles have focused on the formation and composition of microparticles as well as on 
their clearance and vascular effects [3, 4]. Levels of microparticles are easily measurable in 
body fluids using different techniques such as protein concentration, flow cytometry, or 
ELISA assays associated with their pro-coagulant activity. Using the two latter approaches, it 
is possible to quantify the total levels of microparticles as well as their origin through specific 
determination of their surface antigens. Moreover, microparticles can also be measured from 
solid tissues such as atherosclerotic plaque, liver or tumors [5, 6]. 
It should be noted that other types of vesicles such as exosomes and apoptotic bodies are also 
detectable in fluids though the mechanisms governing the release of these vesicles are 
different (see Table 1). Thus, exosomes of size < 0.1 µm are released upon fusion of the 
limiting membrane of multi-vesicular bodies with the cell surface; their composition is 
completely different to that of microparticles. Indeed, exosomes are formed within endosomes 
by invagination of the limiting membranes resulting in the formation of multivesicular bodies. 
Subsequently, multivesicular bodies fuse with the plasma membrane and release exosomes 
into the extracellular environment [7]. The identification of exosomes is based on 
morphological and biochemical criteria. Thus, exosomes are obtained after high speed 
centrifugation (> 100,000 g) and express exosomal markers such as tetraspanins, heat shock 
protein (HSP)70 or HSP90. 
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Apoptotic bodies (size > 1µm) are formed by indiscriminate plasma membrane blebbing and 
possess nuclear fragments and histones [8]. These different populations of vesicles can be 
separated according to the physical characteristics of the shed vesicles. Serial steps of 
centrifugation are routinely used as sequential separation of cells, debris, apoptotic bodies, 
microparticles and exosome fractions. Indeed, microparticles can be isolated from the 
resulting supernatant after cell debris separation through additional centrifugation at < 
100,000 g whereas exosomes are isolated after centrifugation at > 100,000 g. (Table 1). 
Differentiation between exosomes, apoptotic bodies and microparticles is also possible by 
electron microscopy or flow cytometry, although there are claims that exosomes would be too 
small to be detected by flow cytometry. 
Molecular profiling approaches using proteomic techniques, performed in order to determine 
the protein composition of microparticles, have shown that protein composition depends not 
only on cell type, but also on the conditions of cell stimulation [9, 10]. Furthermore, 
differential lipid composition of microparticles may vary depending on the lipidic 
environment surrounding cells; thus it is possible that microparticles from patients with 
metabolic pathologies associated with lipid alterations may have different lipid composition 
which may account for different functional effects of microparticles on target cells. However, 
this hypothesis has been little studied. Thus, circulating levels of microvesicles from platelets 
[11] and tissue-factor-positive microvesicles from T cells or neutrophils [12] negatively 
correlate with plasma HDL levels. Finally, with regard to microparticle composition, it has 
been reported that microparticles envelope and protect mRNA and miRNA from extracellular 
ribonuclease degradation and in this way represent veritable cargo allowing intercellular 
communication [13]. 
Microparticles are biomarkers for cardiovascular pathologies 
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Circulating levels of microparticles are increased in numerous cardiovascular pathologies 
linked to inflammatory and/or pro-coagulant states, and in other diseases such as cancer, 
sepsis and HIV, for instance [3]. With regard to the pathologies associated with 
cardiovascular complications, microparticles from platelets are the major subpopulation of 
circulating microparticles and in general, their levels are enhanced in cardiovascular diseases. 
However, other microparticle subpopulations such as those from endothelial cells, red cells or 
leukocytes can also be increased as described in the metabolic syndrome [14], acute coronary 
syndrome [15], severe hypertension [16] and type 2 diabetes [17]. All these pathologies are 
associated with endothelial dysfunction and microcirculation disturbances suggesting that 
microparticles may, at least in part, play a key role in the pathogenesis of these diseases. 
When detected in blood, microparticles originate from platelets – the main subpopulation 
(almost 80% of total circulating microparticles) – leukocytes, erythrocytes and endothelial 
cells. One of the major functions of blood platelets in haemostasis is to provide a membrane 
surface that accelerates blood coagulation and promotes the formation of the fibrin network in 
the haemostatic plug [18]. By producing microparticles displaying prothrombin-converting 
activity, platelets are able to increase the procoagulant potential. In addition, when stimulated 
in vitro, platelets are the cells that produce microparticles most rapidly. However, although 
circulating levels of platelet-derived microparticles are often increased under pathological 
conditions, changes in other subpopulations of microparticles, such as non-platelet-derived 
microparticles or more specifically endothelial-derived microparticles, seems to have more 
significant pathological relevance [15, 19, 14]. In this respect, microparticles originating from 
a specific cell may be a signature of injury of that type of cells. As an example, endothelial 
microparticles have been considered to be predictors of endothelial dysfunction in arterial 
erectile dysfunction patients with insulin resistance [20]. 
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Total circulating microparticles or those from a specific subpopulation can be correlated with 
the severity of different pathologies and, in this way, they can be considered as circulating 
biomarkers in the surveillance of disease progression. For instance, platelet-derived 
microparticles are positively associated with abnormal carotid and intima-media thickness and 
body mass index in obese patients [21]. In addition, microparticles from platelets positively 
correlate with plasma glucose and insulin levels whereas microparticles from T-helper cells 
positively and negatively correlate with body mass index (BMI) and HDL-cholesterol, 
respectively [12].  
Recently, it has been shown that microparticles derived from endothelial and endothelial-
progenitor cells (EPCs) are positively correlated with blood glucose concentration and infarct 
volume after ischemic cerebral injury in obese leptin-receptor-deficient db/db diabetic mice 
[22]. These findings suggest that microparticles from EPCs and endothelial cells could be 
used as predictive biomarkers for ischemic stroke complication in diabetes, and targeting 
microparticles might offer new therapeutic avenues for diabetes and ischemic stroke. Levels 
of endothelial-derived, but not leukocyte-derived, microparticles are higher in hypertensive 
diabetic patients than in those without hypertension [23]. Endothelial-derived microparticles 
were shown to be an independent risk factor for the presence of hypertension in diabetic 
patients [23]. 
Microparticles as effectors implicated in the maintenance of cardiovascular diseases 
During the last ten years, efforts have been focused on showing that microparticles can be 
effectors capable of delivering biological messages to target cells. Due to its crucial 
localization, one of the main targets of microparticles is the endothelium, the key component 
of the microcirculation contributing to the local balance between relaxing and constricting 
mediators, that regulates hemostasis and vascular permeability. Whereas normal shear stress 
controls homeostasis of the endothelial monolayer, alterations in shear stress induce 
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imbalance in the release of endothelial-derived factor leading to endothelial dysfunction. 
Among these alterations, a decrease of nitric oxide (NO) release and bioavailability, an 
increase of vasoconstrictor factors and an enhanced oxidative stress favor a disturbance of 
vascular reactivity, induce vascular inflammation and remodeling by up-regulating gene 
expression. Theoretically, all of these vascular events can be mediated by microparticles. 
Thus, endothelial cells can participate in microparticle production and simultaneously be 
target cells of endothelial-derived microparticles. Very recently, disturbed blood flow in the 
forearm of healthy young men was shown acutely to induce endothelial activation, as 
reflected by release of microparticles from endothelial cells [24]. The authors of that study 
suggested that in atheroprone arteries from elderly subjects and/or in subjects with risk factors 
such as obesity or type 2 diabetes, the effects might be even more pronounced. Moreover, that 
type of microparticle may participate in a vicious cycle of vascular injury by acting directly 
on the neighboring endothelial cells 
The mechanisms by which microparticles transfer biological information to target cells are 
not completely elucidated, but they may involve: (i) direct ligand-receptor interaction, (ii) 
transfer of surface receptors, proteins, mRNA, miRNA and bioactive lipids, (iii) fusion of 
microparticle and target-cell membranes and (iv) microparticle internalization. Whereas direct 
ligand-receptor interaction leads to activation or inhibition of a transduction signal in target 
cells, the other three mechanisms implicate changes in the phenotype of recipient cells (for 
more details see [2]). For instance, microparticles carrying the morphogen Sonic hedgehog 
(Shh) are able to activate a cascade interacting with its receptor Patched/Smoothened in target 
cells and thereby to induce endothelial angiogenesis and nitric oxide production [25, 26]. 
However, after 2 hours of incubation, these microparticles are internalized into endothelial 
cells and induce overexpression of antioxidant enzymes [27]. These changes are frequently 
due to the horizontal transfer of the microparticle content towards target cells. 
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Microparticles as markers and mediators of biological message in metabolic syndrome 
and its individual components 
The metabolic syndrome (MetS) is a cluster of cardio-metabolic abnormalities including 
visceral obesity, high blood pressure, hyperglycaemia and dyslipidaemia [28, 29], which are 
associated with increased risk of cardiovascular disease and type 2 diabetes [28-30]. The 
prevalence of MetS is increasing because of an increased incidence of overweight, obesity 
and physical inactivity and it continues to provide challenges for medical research beyond its 
clinical and public-health importance [30-32]. The pathophysiology of MetS seems to be 
largely attributable to insulin resistance with the implication of excessive flux of fatty acids 
[33, 34], but also to a pro-inflammatory state resulting from the production of cytokines from 
adipocytes and macrophages [34, 29, 35]. Thus, increased inflammatory factors and reactive 
oxygen species (ROS) are associated with detrimental cardiovascular alterations linked to the 
MetS. Inflammation is orchestrated by the interactions between inflammatory cells (such as 
leukocytes) and vascular cells (endothelial and smooth muscle cells) which under activation 
or apoptosis (for example), lead to the release of circulating microparticles [36, 3, 2]. 
Increased levels of circulating microparticles have been reported in MetS, but also in 
individual components of the condition. In the next sections, we will summarize the effects of 
microparticles of different cellular origin during cardiovascular disease associated with 
metabolic alterations. Table 2 summarizes the types of cardiovascular dysfunctions associated 
with increased levels of circulating microparticles in animals and humans in the context of 
MetS and its individual components. 
Hypertension 
Several studies have shown that circulating microparticles are increased in hypertensive 
patients compared to normotensive subjects and in animal models of hypertension. Most of 
these studies have focused on endothelial-derived microparticles as possible biomarkers of 
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vascular dysfunction and adverse cardiovascular risk. Preston et al. [16] compared levels of 
circulating endothelial- (CD31
+
/CD42
-
) and platelet-derived (CD41
+
) microparticles in 
patients with severe uncontrolled hypertension, untreated patients with established mild 
hypertension and normotensive volunteers. The two hypertensive groups were matched for 
coexisting risk factors. The levels of endothelial microparticles were elevated in patients with 
mild hypertension compared to control subjects, but were even higher in the severe 
hypertensive patients than in the other groups. Moreover, although platelet-derived 
microparticles were enhanced in severely hypertensive patients, they did not differ between 
mild-hypertension and control subjects. Both endothelial- and platelet-derived microparticles 
positively correlated with the absolute level of systolic and diastolic blood pressure; however, 
only endothelial microparticles positively correlated with presence of diabetes mellitus and 
smoking. In the study by Wang et al. [37], circulating endothelial microparticles 
(CD31
+
/CD42
-
) and brachial-ankle pulse wave velocity were evaluated in uncontrolled 
hypertensive patients, well-controlled hypertensive patients and in normotensive healthy 
subjects. Uncontrolled hypertensive patients exhibited higher levels of circulating endothelial 
microparticles and faster brachial-ankle pulse-wave velocity compared to the two other 
groups. Interestingly, a robust positive linear correlation was observed between amounts of 
circulating endothelial microparticles and values of brachial-ankle pulse-wave velocity. 
Nomura et al. [38] also observed that microparticles of platelet and endothelial origin were 
significantly increased in hypertensive patients compared to healthy controls. Another human 
study by Lee and colleagues [39] found that hypertensive patients with micro-albuminuria or 
macro-albuminuria had increased endothelial apoptotic microparticles (defined as 
CD31
+
/Annexin V
+
). Endothelial apoptotic microparticle levels also tended to increase in 
hypertensive patients with electrocardiographic left-ventricular hypertrophy which is 
indicative of hypertensive target-organ damage and strongly predictive of future 
cardiovascular morbidity and mortality [40]. Pre-hypertension, the situation that precedes 
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clinical hypertension, is a very frequent condition associated with increased cardiovascular 
risk and is a component of many cases of MetS [41, 42]. Giannotti and co-workers [43] 
demonstrated that although in vivo endothelial repair capacity of early EPCs was dramatically 
impaired in patients with newly diagnosed prehypertension and hypertension, this was not 
associated with increased levels of circulating endothelial apoptotic microparticles. By 
investigating only endothelial apoptotic microparticles (CD31
+
/Annexin V
+
 particles), the 
authors may have underestimated the total number of circulating endothelial microparticles. 
Indeed, several other studies indicate that fewer than 50% of microparticles actually expose 
phosphatidylserine (Annexin V
+
) [14, 44]. The authors did not search other microparticle sub-
populations which can be altered in pre-hypertension state. Further studies are therefore 
needed to draw a complete picture of how microparticle phenotype evolves with the 
progression and establishment of essential hypertension. Other studies in experimental models 
of hypertension have also shown increased levels of microparticles in hypertension. Recently, 
López Andrés et al. [45] found that aldosterone-salt hypertensive rats had increased 
circulating levels of total microparticles, platelet (CD61
+
)-, endothelial (CD54
+
)- and 
erythrocyte (CD235
+
)-derived microparticles than control animals. The elevation in 
microparticle levels was accompanied by increases in aortic stiffness, oxidative and 
nitrosative stress and microvascular endothelial dysfunction as well as induction of apoptosis 
in the vessel wall. Interestingly, treatment of rats with red-wine polyphenols prevented 
changes in microvascular endothelial dysfunction, oxidative and nitrosative stress and 
apoptosis, but perhaps more importantly, normalised the levels of circulating microparticles. 
Conventional hypertension treatments were shown in several human studies to modulate the 
numbers and phenotype of circulating microparticles. The angiotensin II blocker losartan was 
found to decrease both systolic and diastolic blood pressure in hypertensive patients with and 
without type 2 diabetes mellitus in addition to reducing circulating levels of monocyte-
derived microparticles [18]. The combination of losartan treatment with a statin (simvastatin) 
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further decreased the levels of monocyte-derived microparticles in these patients [18]. 
Another study found that patients with stage 1 and 2 hypertension had high levels of activated 
platelet microparticles compared to controls and that eprosartan treatment (600 mg per day, 
for one or two months) normalised patient’ microparticle levels [46]. Long term treatment of 
diabetic hypertensive patients with the calcium antagonist, nifedipine, normalized levels of 
circulating monocyte- and platelet-derived microparticles [47]. These results suggest that 
microparticles may be implicated in the pathogenesis of hypertension and that changes in 
their circulating levels may be indicative of treatment efficacy in hypertension. 
Diabetes 
Accumulating evidence in the literature indicate that circulating microparticle levels are 
higher in diabetic patients and in animal models of diabetes and that these microparticles may 
play an important role in diabetic vascular complications. Sabatier et al. [48] explored the 
number and the pro-coagulant activity of cell-derived microparticles in type 1 and 2 diabetic 
patients and found that both groups of patients had increased levels of circulating 
microparticles. Nevertheless, diabetic patients differ by the pro-coagulant activity and the 
cellular origin of their circulating microparticles. Type 1 diabetic patients exhibited 
significantly increased levels of platelet-, and endothelial-derived and pro-coagulant 
microparticles (Annexin V
+
), and increased levels of microparticle-associated pro-coagulant 
activity than non-diabetics or type 2 diabetics. In type 2 diabetes patients, only pro-coagulant 
microparticles were significantly increased over those of control subjects without an increase 
in their pro-coagulant activity [48]. A more recent study by Feng et al. [49] showed, however, 
that type 2 diabetic patients presented higher circulating levels of pro-coagulant, platelet, 
leukocyte, and endothelial microparticles than did non-diabetic volunteers. In that cohort, the 
authors also showed that among the increased sub-types of microparticles, only those derived 
from the endothelium were associated with vascular dysfunction in diabetic patients. 
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Endothelial microparticles correlated positively with glycated haemoglobin (HbA1c) and 
brachial-ankle pulse-wave velocity, but negatively correlated with flow-mediated dilation 
(FMD) [49]. A study by Nomura and co-workers [50] also reported increased plasma levels of 
microparticles of endothelial, monocyte and platelet origins in patients with type 2 diabetes 
compared to control subjects. This research also demonstrated that the presence of other 
comorbidities, such hypertension, with diabetes further increased the numbers of circulating 
microparticles [50]. Other studies also showed association between endothelial microparticle 
levels and diabetic complications. For instance, Koga et al. [51] found a two-fold increase in 
endothelial-microparticle (CD144
+
) levels in diabetic patients in comparison to healthy 
subjects. Endothelial-microparticle levels were significantly higher in diabetic patients with 
coronary artery disease than in those without. In that cohort, the elevated endothelial 
microparticle levels were found to be a significant independent predictor for the presence of 
coronary artery disease in patients with diabetes mellitus. Another study by Bernard et al. [52] 
investigated the levels of endothelial and platelet microparticles and the presence of coronary 
non-calcified plaques in 56 type 2 diabetic patients. These authors found that endothelial-
derived microparticles (CD144
+
) were significantly increased in patients with coronary non-
calcified plaque. Recently, Tsimerman and co-workers [53] characterised the cell origin and 
pro-coagulant profiles of microparticles from 41 healthy volunteers and 123 type 2 diabetics 
with coronary artery disease, retinopathy and foot ulcers. The authors observed that diabetic 
patients had increased amounts of microparticles which were predominantly of platelet origin. 
Patients with severe diabetic foot ulcers expressed the highest levels of pro-coagulant 
(Annexin V
+
) microparticles and those originating from platelets and endothelial cells. They 
also found that the microparticle pro-coagulant activity was higher in diabetics with coronary 
artery disease and foot ulcers than in healthy subjects and in patients with diabetic 
retinopathy. Interestingly, microparticles from diabetic patients increased endothelial cell 
coagulation activity and the most pro-coagulant microparticles were those from patients with 
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severe diabetic foot ulcers, indicating that these microparticles may participate in thrombosis 
observed in diabetes. Furthermore, diabetic microparticles impaired the angiogenic capacity 
of human umbilical vein endothelial cells (HUVECs) grown on a matrigel. HUVECs 
incubated with microparticles from diabetics with coronary artery disease were unable to form 
tube-like networks, whereas cells incubated with microparticles from diabetics with 
retinopathy or foot ulcers induced branched-tube networks that were unstable and quickly 
collapsed [53]. These results suggest that microparticles may be implicated, at least in part, in 
the failed angiogenesis described in diabetic patients. Microparticles from other origins were 
also associated with diabetes complications. Platelet- and monocyte-derived microparticles 
for example were reported to increase with the progression and severity of diabetic 
retinopathy [54, 55]. In animal models of diabetes, it has been recently observed that db/db 
diabetic mice had increased circulating endothelial-derived microparticles and impaired 
cerebral microvascular density [22]. The authors also reported that circulating microparticles 
from db/db diabetic mice impaired EPC functions and infusion of EPCs pre-incubated with 
db/db microparticles failed to reduce ischemic damage in db/db mice [22]. 
Several human studies evaluated the modulation of circulating microparticle levels by 
diabetes treatments. Recently, Esposito et al. [56] compared the effects of pioglitazone and 
metformin on circulating levels of endothelial microparticles and EPCs in patients with newly 
diagnosed type 2 diabetes. Authors reported that 24-week pioglitazone treatment significantly 
reduced numbers of endothelial microparticles and increased those of EPCs [56]. The 
treatment of patients with type 2 diabetes for four months with the oral anti-diabetic drug 
miglitol (150 mg/day) was shown to decrease significantly plasma levels of platelet-derived 
microparticles [57]. Another oral anti-diabetic drug, acarbose, was also found to reduce 
plasma levels of platelet-derived microparticles in patients with type 2 diabetes [58]. Statin 
treatment was also reported to alter microparticles in diabetic patients. Sommeijer et al. [59] 
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found that statin, pravastatin, treatment did not change numbers of plasma microparticles 
from different origins in type 2 diabetics; however, it had an effect on the membrane 
composition of platelet-derived microparticles. The authors evaluated the intensity of 
Annexin V, tissue factor and Glycoprotein IIIa (GPIIIa) staining per microparticle. They 
found that GPIIIa expression per platelet-derived microparticle was significantly decreased 
after pravastatin therapy indicating reduced platelet activation [59]. 
These findings highlight the importance of circulating microparticles as markers of the 
severity of diabetes and support their potential use as tools to monitor the efficacy of 
treatments. 
Dyslipidaemias 
Few studies have investigated the levels and cellular origins of circulating microparticles in 
subjects with dyslipidaemia alone and not in conjunction with other risk factors. The work by 
Pirro et al. [60] characterized circulating endothelial-derived microparticles, circulating EPCs 
and aortic pulse-wave velocity, a marker of aortic stiffness, in 50 patients with newly 
diagnosed never-treated frank hypercholesterolemia and 50 normo-cholesterolaemic control 
subjects. In that study, subjects with secondary hyperlipidaemia caused by diabetes or another 
disease, history of cardiovascular disease, hypertension, evidence of atherosclerotic plaques, 
or with any clinical or laboratory evidence of inflammation were excluded. The authors found 
that hyper-cholesterolaemic patients had a higher ratio of endothelial microparticles to EPCs 
than normo-cholesterolaemic subjects, as a result of both an increased number of endothelial 
microparticles and reduced peripheral EPCs. Endothelial microparticles and EPCs levels 
correlated negatively in this cohort. Furthermore, endothelial microparticle levels robustly and 
positively correlated with both LDL-cholesterol and aortic stiffness. A multivariate linear 
regression analysis showed that high plasma cholesterol and a high ratio of endothelial 
microparticles to EPCs independently predicted an increased aortic pulse-wave velocity [60]. 
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Another study by Nomura et al. [61] demonstrated that hyper-lipidaemic patients without type 
2 diabetes had increased circulating amounts of both monocyte- and platelet-derived 
microparticles than normo-lipidaemic controls. A more recent study from the same group [7] 
evaluated the levels of circulating platelet-derived microparticles in 68 patients with 
hyperlipidaemia at baseline and after 6 months of treatment with pitavastatin (2 mg per day). 
However, the authors reported no changes in the levels of platelet-derived microparticles after 
treatment [7]. The levels of circulating endothelial microparticles were shown to increase very 
quickly in relation a postprandial increase in triglycerides in normo-lipidaemic subjects [62]. 
In this research, Ferreira et al. [62] showed that a single high-fat meal significantly increased 
endothelial microparticle levels after one and three hours and positively correlated with a 
postprandial elevation in serum triglycerides. Elevated postprandial plasma triglycerides are 
an established risk factor for cardiovascular disease [63] and several reports have indicated 
that increased postprandial hypertriglyceridemia can impair endothelial function in normo-
lipidaemic subjects [64, 65]. Because cells can respond to whole-body changes by releasing 
circulating microparticles that are able to carry a biological message, microparticles can 
represent an early response to injury and may predict future adverse events in population at 
risk. 
Obesity 
Elevated levels of circulating microparticles from different cellular origins were reported in 
various clinical cohorts. Recently, Gündüz and colleagues [66] investigated circulating levels 
of endothelial-derived microparticles, carotid artery intima-media thickness and left 
ventricular mass index in 55 obese and overweight children and 23 healthy controls. The 
group reported that blood pressure, endothelial microparticle levels, and left ventricular mass 
index were significantly increased in the obese/overweight group compared to control 
subjects. Furthermore, they observed a linear correlation between blood pressure, endothelial 
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microparticles and overweight and obesity. This study suggested that endothelial damage 
starts in the early stages of childhood obesity [66]. Another cross-sectional cohort study 
recently evaluated the levels of different markers of platelet activation and their relationship 
with carotid intima media thickness along with other atherosclerotic risk factors in obese 
patients with or without atherosclerotic co-morbidities [21]. This work indicated that platelet-
derived microparticles were markedly increased in obese subjects compared to healthy 
volunteers and when obese patients were compared to each other; those with further cardio-
metabolic co-morbidities had even higher levels of these microparticles. In addition, platelet-
derived microparticle levels positively correlated with most parameters of cardiovascular risk 
such as BMI, waist circumference, fasting plasma glucose level, homeostasis model 
assessment (HOMA) and triglycerides. Furthermore, carotid intima media thickness had a 
significant and positive univariate association with platelet-derived microparticles. Multiple 
regression analysis showed also strong independent association between platelet-derived 
microparticle levels and BMI [16]. Previous work by Esposito and colleagues [67] 
characterized circulating levels of platelet- and endothelial-derived microparticles and FMD 
in 41 obese and 40 normal weight women. Obese women, when compared to lean controls, 
had increased circulating amounts of both platelet- and endothelial-derived microparticles and 
reduced values for FMD. In that study, BMI did not correlate with either platelet- or 
endothelial-derived microparticles, while waist-to-hip ratio significantly correlated with both 
types of microparticles. The impairment of FMD in obese women demonstrated a robust 
correlation with both platelet- and endothelial-derived microparticles; however, multivariate 
analysis indicated that only endothelial microparticles were an independent predictor of 
impaired endothelium-dependent vasodilation [67]. Strategies to reduce weight have been 
shown to modulate the numbers of specific sub-populations of circulating microparticles that 
are increased in obese subjects, further indicating a link between overweight/obesity and the 
elevation of circulating microparticles. For instance, Morel et al. [68] subjected 24 obese 
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women to a very low-calorie diet for 90 days. Biomarkers of vascular damage and circulating 
levels and origins of microparticles were determined before, 30 and 90 days after starting the 
diet. At 90 days of diet, weight reduction was significantly associated with reduction of pro-
coagulant, leukocyte and lymphocyte microparticles together with improved cardio-metabolic 
parameters such as leptin levels and blood pressure [68]. Owing to the strong correlation 
between microparticle circulating levels and cardiovascular risk factors in obese people, the 
monitoring the circulating levels of microparticles may be regarded as an interesting tool to 
evaluate the efficiency of life-style interventions or treatments on the reduction of 
cardiovascular risk in obese people.  
Metabolic Syndrome (MetS) 
We have seen above that individual cardio-metabolic risk factors are associated with 
increased levels of circulating microparticles of different origin that correlated with the 
progression or severity of cardiovascular risk. The association of several cardio-metabolic risk 
factors within one subject and how together they influence the count and phenotype of 
circulating microparticles have also attracted the interest of the scientific community in recent 
years. With this in mind, different research groups have studied the levels and cellular origins 
of circulating microparticles in cohorts of subjects with MetS, a cluster of cardio-metabolic 
risk factors. A study by Agouni et al. [14] determined the count and phenotype of circulating 
microparticles in 43 well-characterized MetS patients and 37 healthy volunteers and assessed 
the effects of these microparticles on endothelial function both in vitro and in vivo in mice. 
The authors reported that MetS patients had increased circulating levels of microparticles 
compared with healthy volunteers, including pro-coagulant microparticles and microparticles 
of platelet, endothelial and erythrocyte origin. They also demonstrated that microparticles 
from MetS patients altered NO signaling pathways, decreased NO production in vitro in 
cultured endothelial cells, and impaired endothelium-dependent relaxation in response to 
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acetylcholine in the aorta of mice injected with these microparticles. Of particular interest, the 
authors found that although platelet-derived microparticles represent the predominant sub-
population in MetS patients, the effects of MetS microparticles on endothelial function were 
driven by non-platelet microparticles [14]. More recent work from the same group [69] 
extended the investigation of the role of circulating microparticles in the pathophysiology of 
MetS to their effects on the smooth muscle. The authors observed that MetS microparticles 
injected into healthy mice were able to interact with smooth muscle cells causing vascular 
hypo-reactivity in response to vasoconstrictor agonists by triggering inflammation in the 
vascular wall and, particularly, by up-regulating inducible nitric oxide synthase (iNOS) and 
NO production. They also demonstrated that MetS microparticles interact with smooth muscle 
cells through the Fas/Fas-ligand death pathway to cause vascular hypo-reactivity in response 
to vasoconstrictors [69].  
Similar findings on microparticle phenotyping have been described by Helal et al. [70]. They 
reported in a bicentric cohort of MetS patients and healthy controls that patients had 
significantly higher circulating levels of platelet-, erythrocyte- and endothelial-derived 
microparticles in addition to pro-coagulant microparticles than MetS-free controls. In that 
study, multivariate analysis showed that waist circumference positively influenced the level of 
both platelet and endothelial microparticles. BMI positively correlated with pro-coagulant and 
endothelial microparticles and blood pressure positively influenced the level of endothelial 
microparticles [70]. Previous studies have also addressed microparticles in patients with 
MetS. Arteaga et al. [71] reported endothelial-cell microparticle release, platelet and 
leukocyte activation and increased binding of microparticles from endothelial cells and 
platelets to leukocytes in patients with the MetS, whereas Ueba et al. [72] reported that 
platelet microparticle levels were predictive of MetS. Chironi and colleagues [73] showed that 
MetS patients exhibited higher leukocyte-derived microparticle levels than those free of such 
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syndrome and, in the overall study population, that leukocyte-derived microparticle levels 
increased gradually in parallel with the number of components of MetS. Possible reasons for 
these inconsistent observations between studies are differences in methods used for 
microparticle isolation and quantification and in patient-selection criteria. 
Altogether, these findings suggest that microparticles could be used as predictive biomarkers 
of cardiovascular pathologies associated with the coexistence of several cardio-metabolic risk 
factors. For instance, other cardiovascular risks such as smoking should be considered as 
factors able to modify the level and the type of circulating microparticles. Whereas Grant and 
collaborators [74] have described reduced levels of circulating plasma-derived microvesicles 
(mix of microparticles and exosomes) in smokers, other workers have found an increase in 
endothelial-derived microparticles [75] and unchanged levels of procoagulant microparticles 
[76]. Moreover, in vitro exposure of macrophages to tobacco smoke can directly induce the 
release of a mix of microparticles and exosomes carrying gelatinolytic and collagenolytic 
activities, mainly through the protease MMP14. These vesicles may be novel mediators of 
clinically important matrix destruction in smokers [77]. 
Future directions 
As described above, levels of circulating microparticles are a factor in multiple cardiovascular 
diseases such that it would be possible to evaluate changes in circulating microparticle levels 
in response to pharmacological treatment (for review see [3]). Several studies indicate that a 
reduction in the levels of total, or a specific population of, circulating microparticles could 
indicate the efficacy of a treatment or disease regression. In addition, modulation of 
microparticle levels by drug treatment could reduce the deleterious effects of microparticles. 
For example, treatment of patients with ischemic cardiomyopathy with atorvastatin 
significantly decreased plasma levels of endothelial-derived microparticles together with 
increasing numbers of EPCs [78]. Furthermore, in patients with peripheral arterial occlusive 
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disease, atorvastatin treatment reduced the expression of tissue factor, GPIIIa and P-selectin 
in platelet-derived microparticles thus inhibiting initiation of thrombin generation [79]. 
Further analyses of microparticle detection and quantification for each patient could allow 
personalized therapy. For the moment, standardization of the method of isolation and 
detection of microparticles is needed [80]. 
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Figure 1. Mechanisms through which microparticles participate to the pathophysiology of 
cardiovascular diseases. Cell stimulation or apoptosis lead to microparticle shedding. Microparticles 
can interact with endothelial cells and alter the NO-pathway and reactive oxygen species production 
leading to reduced bio-availability of NO and impairing thus vascular relaxation. Microparticles also 
can stimulate smooth muscle cells, through for example Fas/FasL interaction, causing vascular hypo-
reactivity. Circulating microparticles may bind coagulation factors and activate platelets enhancing 
thus coagulation. Microparticles can stimulate EPCs and reduce their tissue damage repair capacity 
and can also impair the angiogenic capacity of endothelial cells. Microparticles can stimulate 
lymphocytes and endothelial cells to produce cytokines and other inflammatory mediators. Arrows 
with (-) indicate an inhibitory effect and arrows with (+) indicate a stimulatory effect. 
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Table 1. 
 Apoptotic bodies Microparticles Exosomes 
Size > 1 µm 0.1-1 µm <0.1 µm 
Isolation < 15,000 g 15,000 – 21,000 g > 100,000 g 
Density (g/ml) 1.16-1.28 Unknown 1.13-1.19 
Methods of 
detection 
 
Flow cytometry, 
immunofluorescence, 
electron and atomic force 
microscopies, light 
scattering technique, 
western blotting, 
ELISA-based tests 
 
Flow cytometry, 
immunofluorescence, 
electron and atomic force 
microscopy, light 
scattering technique, 
western blotting, 
ELISA-based tests 
 
Immunofluorescence, 
electron microscopy, 
light scattering 
technique, western 
blotting, ELISA-based 
tests 
 
Interaction 
with target 
cells 
Transfer 
Fusion 
Internalization 
Ligand-receptor 
Transfer 
Fusion 
Internalization 
Ligand-receptor 
Transfer 
Fusion 
Internalization 
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Table1. Summary of the cardiovascular dysfunctions associated with increased levels of 
circulating microparticles in animals and humans in MetS and its individual components 
Component Microparticle origin Animal models Humans References 
Hypertension Endothelial 
 
 
 
Endothelial/apoptotic 
 
 
Endothelial cells , 
platelets, and 
erythrocytes 
 
 
 
 
 
 
 
Aortic stiffness, 
microvascular 
endothelial 
dysfunction (ex 
vivo) 
Faster brachial 
ankle pulse-wave 
velocity (in vivo) 
 
left-ventricular 
hypertrophy (in 
vivo) 
[37] 
 
 
 
[40] 
 
 
[45] 
Diabetes Pro-coagulant, platelets 
and endothelial cells 
 
 
Pro-coagulant, platelets, 
leukocytes, and 
endothelial cells 
 
 
 
Endothelial cells 
 
 
Pro-coagulant, platelets 
and endothelial cells 
 
 
Platelets and monocytes 
 
 
 
Endothelial cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impaired cerebral 
microvascular 
density and 
impaired EPC 
functions (in vivo 
and ex vivo) 
Increased pro-
cogulant activity 
(ex vivo) 
 
Faster brachial-
ankle pulse-wave 
velocity and 
reduced FMD (in 
vivo) 
 
Coronary artery 
disease (in vivo) 
 
Impaired 
angiogenesis (ex 
vivo) 
 
Progression and 
severity of 
retinopathy (in 
vivo) 
 
 
[48] 
 
 
 
[49] 
 
 
 
 
 
[51, 52] 
 
 
[53] 
 
 
 
[54, 55] 
 
 
 
[22] 
Dyslipidaemias Endothelial cells  Aortic stiffness 
and decreased 
EPCs numbers (in 
vivo) 
 
[60] 
Obesity Endothelial cells 
 
 
 
Platelets 
 
 
 
 
Platelets and endothelial 
cells 
 Increased left 
ventricular mass 
index (in vivo) 
 
Increased carotid 
intima media 
thickness (in 
vivo) 
 
Reduced FMD (in 
vivo) 
[66] 
 
 
 
[21] 
 
 
 
 
[67] 
 
MetS Pro-coagulant, platelets, 
erythrocytes and 
endothelial cells 
 
 
Endothelial cells, 
leukocytes and platelets 
 
Endothelial 
dysfunction and 
vascular hypo-
reactivity (in vivo 
and ex vivo) 
 
 
 
 
 
 
Microparticles 
are predictive of 
MetS (in vivo) 
[14, 69] 
 
 
 
 
[72, 73] 
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